Markets:

Overview

News

Currencies

International

Treasuries

Awakn Life Sciences Corp (OP:AWKNF)

0.0650 UNCHANGED

Last Price Updated: 3:11 PM EST, Dec 13, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Awakn Life Sciences Corp

< Previous 1 2 3 4 5 Next >

Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More ↗

March 07, 2023

Psychedelics Bills Around The Country: 9 New Proposals, Several Passes, Several Fails And A Successful Local Decriminalization Throughout the 2023 session, numerous discussions have been...

Via Benzinga

MDMA News: Exclusive Supply Deal With Awakn Life Sciences & Canadian Company Expands Psychedelics Production ↗

March 02, 2023

PharmAla To Be Exclusive MDMA Supply Partner To Awakn Life Sciences Effective immediately, MDXX class molecules producer PharmAla Biotech Holdings Inc. will become the exclusive MDMA supplier to Awakn...

Via Benzinga

Latest Psychedelics Deals: Optimi Supplies Australia, Awakn Partners Licensing In California ↗

March 02, 2023

Optimi Health Enters Australian Medical Psychedelics Market Via Mind Medicine Australia

Via Benzinga

Psyched: Hawaii And Minnesota's Bills, Studying 2C-B Vs. Psilocybin, Filament CEO, Plus Brock Pierce And Jeremy Gardner Discuss The Industry's Future And More ↗

February 27, 2023

Two Bills Approved By Hawaii Senators With Governor's Endorsement Hawaii Senate Ways and Means Committee approved a pair of bills aiming to promote and investigate the therapeutic potential of MDMA and...

Via Benzinga

Awakn's First Licensing Partnership Deal In Europe Involves Chain Of Portuguese Clinics ↗

February 22, 2023

Awakn Life Sciences Corp. (OTCQB: AWKNF) has signed a licensing partnership agreement in Europe with a Portugal-based healthcare consortium currently operating in stealth mode.

Via Benzinga

Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More ↗

February 21, 2023

Psychedelics States Reform: Utah, Iowa, Missouri and Oklahoma’s New Bills; Hawaii, Arizona and Washington's Green Lights, New Hampshire's Setback Earlier this week, three bills were introduced and...

Via Benzinga

Psychedelics For Alcohol Use Disorder: Awakn Opens European Clinic, FSD Launches R&D Program ↗

February 14, 2023

Awakn Opens Fourth European Clinic, Norway Takes Center Stage

Via Benzinga

Psyched: 12 States Discuss Legalization Bills, Ceremonies For Veterans With TBI, Ketamine And MDMA Fast-Tracks & More ↗

February 13, 2023

Psychedelics Legislation: The Latest On Hawaii, Virginia, Missouri & More

Via Benzinga

A New Way Of Delivering MDMA? Awakn And Tech Partner Are Set To Study Viability ↗

February 09, 2023

Psychedelics biotech Awakn Life Sciences (OTCQB: AWKNF) has initiated a feasibility study of formulating and delivering MDMA through Catalent’s proprietary oral,

Via Benzinga

Awakn Life Sciences Corp Shares Rally 77% After Earning ILAP Expedited Approval Pathway For Its Ketamine-Assisted AUD Therapeutic ($AWKNF)

February 09, 2023

Via AB Newswire

Awakn's Ketamine Treatment For Alcohol Use Disorder Awarded UK's Fast-Track Status ↗

February 07, 2023

Awakn Life Sciences Corp. (OTCQB: AWKNF), a biotech company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), has been granted an Innovation Passport for...

Via Benzinga

Awakn Life Sciences Corp Earns Global AUD Treatment Interest With A New Class Of Psychedelics-Based Therapeutic ($AWKNF)

February 07, 2023

Via AB Newswire

Two New Studies On Classical Psychedelics: Grading Ketamine's Components, Tuning Down Psilocybin Dosing ↗

January 24, 2023

Awakn’s First Study On Novel S-Ketamine Formulation To Assess Dissociative Effect

Via Benzinga

What Happened With Psychedelics In The Last Year? 11 Key News Items, The Sector's Performance & Takeaways ↗

January 03, 2023

What a year for psychedelics!

Via Benzinga

6 Largest Psychedelic Drug Stocks Were -20% In December ↗

January 02, 2023

The Psychedelic Drug Stocks Index, which tracks the six largest psychedelic stocks researching the treatment of mental illnesses based on the use of one or more psychedelic substances, continued to...

Via Talk Markets

Largest Psychedelic Stocks DOWN 8% Last Week; DOWN 22% So Far This Month ↗

December 25, 2022

Today's article highlights the performance of the munKNEE Psychedelic Drug Stocks Index which tracks the six (6) largest psychedelic stocks researching the treatment of mental illnesses based on the...

Via Talk Markets

Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK's Research Support And More ↗

December 19, 2022

Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans The first medical-grade drug candidate of the psychedelic ayahuasca is being developed.

Via Benzinga

Awakn Unveils Q3 Results, Touts Revenue Growth, R&D Progress, Commercial Plans ↗

December 16, 2022

Psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) shared its financial results and business highlights for a three-month period that ended Oct. 31, 2022. Financials showed:

Via Benzinga

UK Supports Psychedelic Research With Phase 3 Trial In Federal Health Sites ↗

December 13, 2022

Awakn Life Sciences Corp.

Via Benzinga

Major Psychedelic Drug Stocks DOWN 9% Last Week; Now Down 51% YTD ↗

December 11, 2022

Today's article highlights the performance of the largest psychedelic stocks that research the treatment of a variety of mental illnesses based on the use of ten (10) different psychedelic substances.

Via Talk Markets

Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal's Decrim Project ↗

December 06, 2022

Psychedelic Research & Fed Funding By The National Institute Of Mental Health The National Institute of Mental Health (NIMH) named the types of psychedelics studies to which it would grant funds and...

Via Benzinga

Europe To Have Expanded Access To Psychedelic-Assisted Therapy With New Norway Clinic ↗

December 03, 2022

Psychedelics biotech Awakn Life Sciences Corp.

Via Benzinga

Psyched: Full-Dose & Microdosing LSD Studies, Research Scope For Fed Funding, Consumption Sites And More ↗

November 29, 2022

LSD Research Ramps Up: Full-Dose & Microdosing For Alzheimer's Studies Led By Beckley Foundation Coming Soon

Via Benzinga

Psychedelic Drug Stocks Index Has A Good Week ↗

November 27, 2022

We track six psychedelic stocks researching the treatment of a variety of mental illnesses based on the use of 10 different psychedelic substances.

Via Talk Markets

A Leading Ketamine Treatment Clinic For Alcoholism Is Expanding: Here's The Latest ↗

November 23, 2022

A psychedelics R&D biotech company, known for providing novel treatments for addictions, is opening a new ketamine clinic.

Via Benzinga

Psychedelic Drug Stocks Index Continued To Decline Last Week ↗

November 20, 2022

This article highlights the performances of the 6 constituents in the munKNEE Psychedelic Drug Stocks Index last week and in the last 3 weeks and the extent to which each company is likely to encounter...

Via Talk Markets

Psyched: Colorado Legalizes Psychedelics, NYC Treats Alcoholism With Ketamine, $30M Series A For Startup ↗

November 15, 2022

Colorado Voters Approve Initiative To Legalize And Regulate Psychedelics

Via Benzinga

EXCLUSIVE: New Partnership Brings Leading Psychedelic Protocol For Alcoholism Treatment To NYC ↗

November 09, 2022

NYC-based clinics brand Nushama has partnered with Awakn Life Sciences (OTCQB: AWKNF), a clinical-stage psychedelics biotech company to bring

Via Benzinga

Can Ketamine Treat Alcohol Addiction? In-Clinic Therapy Vs. Retreats ↗

October 13, 2022

(Part four of a four-part series - Read part three)

Via Benzinga

Can Ketamine Treat Alcohol Addiction? The Awakn Approach ↗

October 10, 2022

(Part three of a four-part series)

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.